SCHEMBL26113154

SCHEMBL26113154

COc1cc2ncnc(-c3cn(C)nc3-c3ccccc3)c2nc1NC(=O)[C@@]1(C(F)(F)F)CCCN1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
EGFR P00533 6/20 0.34
PDGFRB P09619 2/20 0.33
ERBB2 P04626 1/20 0.33
CSNK1D P48730 3/20 0.33
CSNK1E P49674 3/20 0.33
POLB P06746 1/20 0.32
PDE10A Q9Y233 2/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
BRAF P15056 1/20 0.32
NPC1 O15118 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C19 P33261 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26112345 1.00 HCRTR1 (0.36) HCRTR1HCRTR2EGFRPDGFRBERBB2
SCHEMBL26112337 1.00 HCRTR1 (0.36) HCRTR1HCRTR2EGFRPDGFRBERBB2
SCHEMBL26112581 0.88 EGFR (0.36) HCRTR1HCRTR2EGFRPDGFRBERBB2
SCHEMBL26112695 0.86 EGFR (0.35) HCRTR1HCRTR2EGFRPDGFRBERBB2
SCHEMBL26112448 0.86 EGFR (0.35) HCRTR1HCRTR2EGFRPDGFRBERBB2
SCHEMBL26112460 0.86 EGFR (0.35) HCRTR1HCRTR2EGFRPDGFRBERBB2
SCHEMBL26110777 0.86 HCRTR1 (0.36) HCRTR1HCRTR2EGFRPDGFRBERBB2
SCHEMBL26113701 0.85 IRAK4 (0.36) HCRTR1HCRTR2EGFRERBB2CSNK1D
SCHEMBL30590797 0.84 EGFR (0.36) HCRTR1HCRTR2EGFRPDGFRBERBB2
SCHEMBL26112766 0.84 EGFR (0.36) HCRTR1HCRTR2EGFRPDGFRBERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 US disclosed
EP-4504719-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2025-02-12 EP disclosed
CN-119325471-A EGFR inhibitors 缆图药品公司 2025-01-17 CN disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 HCRTR1 4877/4885HCRTR2 4871/4885EGFR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.